Wen W, Taylor S S
University of California, Department of Chemistry, La Jolla, San Diego 92093-0654.
J Biol Chem. 1994 Mar 18;269(11):8423-30.
The two classes of physiological inhibitors of the catalytic subunit of cAMP-dependent protein kinase are the regulatory subunits and the heat-stable protein kinase inhibitors (PKIs), and both share a common mechanism of inhibition. Each has a similar inhibitor site that resembles a peptide substrate, and this occupies the P-3 to P+1 portion of the peptide recognition site. However, in addition to this consensus site, each inhibitor requires a peripheral binding site to achieve high affinity binding. Arg134 and Arg133 lie on the surface of the catalytic subunit with Arg133 coming close to the amphipathic helix of PKI(5-24) (Knighton, D. R., Zheng, J., Ten Eyck, L. F., Xuong, N.-h., Taylor, S. S., and Sowadski, J. M. (1991) Science 253, 414-420). Replacement of Arg134 and Arg133 with Ala selectively abolishes the high affinity binding of PKI. Replacement of Arg133 alone is sufficient to give the same phenotype. In the presence of MgATP, the Kd,app, is increased from < 0.2 to 105 nM and, in the absence of ATP, the Kd is too large to be reliably measured. Based on the crystal structure, Arg133 hydrogen bonds to the P-7 backbone carbonyl of PKI(5-24). However, more importantly, it also contributes to the hydrophobicity of the P-11 binding site in the C.PKI(5-24) complex. We predict that it is the perturbation of this hydrophobic pocket that accounts for the effects of this mutation. In the absence of peptide, Arg133 may help to stabilize Glu230, a buried carboxylate that binds to the P-2 Arg in the crystal structure of C.PKI(5-24). Replacement of Arg133 and Arg134 with Ala has little effect on catalysis using a heptapeptide substrate and has no effect on the inhibition of the catalytic subunit by the regulatory subunit. The results thus demonstrate that these two inhibitor proteins that both bind to the catalytic subunit with a high affinity utilize different sites on the enzyme to achieve tight binding. The gamma isoform of the catalytic subunit is insensitive to inhibition by PKI and in this isoform Arg133 is replaced with Gln. We predict that this change accounts for the altered inhibitor properties of C gamma.
环磷酸腺苷(cAMP)依赖性蛋白激酶催化亚基的两类生理性抑制剂是调节亚基和热稳定蛋白激酶抑制剂(PKIs),二者具有共同的抑制机制。它们都有一个类似肽底物的相似抑制位点,该位点占据肽识别位点的P-3至P+1部分。然而,除了这个共有位点外,每种抑制剂还需要一个外周结合位点来实现高亲和力结合。精氨酸134(Arg134)和精氨酸133(Arg133)位于催化亚基表面,其中Arg133靠近PKI(5 - 24)的两亲性螺旋(奈顿,D. R.,郑,J.,滕·艾克,L. F.,徐昂,N.-h.,泰勒,S. S.,以及索瓦茨基,J. M.(1991年)《科学》253卷,414 - 420页)。用丙氨酸(Ala)取代Arg134和Arg133会选择性地消除PKI的高亲和力结合。仅取代Arg133就足以产生相同的表型。在存在MgATP的情况下,表观解离常数(Kd,app)从< 0.2 nM增加到105 nM,而在不存在ATP的情况下,Kd太大以至于无法可靠测量。基于晶体结构,Arg133与PKI(5 - 24)的P-7主链羰基形成氢键。然而,更重要的是,它还对C.PKI(5 - 24)复合物中P-11结合位点的疏水性有贡献。我们预测正是这个疏水口袋的扰动导致了这种突变的效应。在不存在肽的情况下,Arg133可能有助于稳定谷氨酸230(Glu230),这是一个埋藏的羧酸盐,在C.PKI(5 - 24)的晶体结构中与P-2精氨酸结合。用丙氨酸取代Arg133和Arg134对使用七肽底物的催化作用影响很小,并且对调节亚基对催化亚基的抑制作用没有影响。因此,结果表明这两种都以高亲和力结合到催化亚基的抑制剂蛋白利用酶上的不同位点来实现紧密结合。催化亚基的γ同工型对PKI的抑制不敏感,在这种同工型中Arg133被谷氨酰胺(Gln)取代。我们预测这种变化导致了Cγ抑制剂特性的改变。